Babies who had standard Kasai surgery when they were more than 60 days old or had spleen malformations were more…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
HEPATITIS
NewsCanada clears fast fingerstick test for hepatitis C
A one-hour point-of-care test for hepatitis C has been cleared for use in Canada, which could help accelerate diagnosis…
FATTY LIVER DISEASE
NewsFDA gives conditional approval to Wegovy for some liver patients
The U.S. Food and Drug Administration (FDA) has conditionally approved Novo Nordisk’s Wegovy (semaglutide) to treat certain people with…
FATTY LIVER DISEASE
NewsNorUDCA becomes first MASLD therapy approved in India
India’s Central Drugs Standard Control Organization has approved the oral therapy nor-ursodeoxycholic acid (NorUDCA) for people with metabolic dysfunction-associated steatotic…
A new artificial intelligence (AI) algorithm can help identify babies with genetic forms of cholestasis, including progressive familial intrahepatic…
FATTY LIVER DISEASE
NewsFatty liver disease linked to projected rise in liver cancer
The proportion of cases of hepatocellular carcinoma (HCC) attributable to fatty liver disease is set to rise in the…
BILIARY ATRESIA
NewsStudy finds a new player behind liver scarring in biliary atresia
A new study has uncovered a key mechanism behind the liver scarring seen in biliary atresia (BA), a rare…
The first participant has been enrolled in ECLIPSE 3, a Phase 2b clinical trial testing Vir Biotechnology’s combination treatment…
CHOLESTASIS
NewsStudy links low vitamin D to severe liver damage in cholestasis
Low levels of vitamin D by-products, or metabolites, in the blood are indicative of more severe liver damage in…
FATTY LIVER DISEASE
NewsStudy testing fatty liver disease MASH therapy almost fully enrolled
Enrollment is nearly complete in a Phase 2b clinical trial that’s testing Corcept Therapeutics‘ experimental oral therapy miricorilant in…